Telik Announces Fourth Quarter and 2011 Year End Financial Results and 2012 Financial Guidance
Bioportfolio,
PALO ALTO, Calif., Feb. 23, 2012 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) reported a net loss of $2.5 million, or $0.05 per…
A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate‐1 risk myelodysplastic syndrome
Overview of attention for article published in Cancer (0008543X), September 2011
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (87th percentile)
-
Good Attention Score compared to outputs of the same age and source (73rd percentile)
Readers on
- mendeley
- 42 Mendeley